Valley Research Trials — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$32,999	11
2022	Research	$478	1
2021	Research	$125,951	165
2020	Research	$71,501	109
2019	Research	$40,355	11

Breakdown

Who paid Research payments · program years 2019–2024

Sanofi US Services Inc. $208,030 260 payments
Galderma Laboratories, L.P. $32,999 11 payments
Sanofi-Aventis U.S. LLC $30,255 26 payments

Studies the money was for Research payments · program years 2019–2024

A 12-week Randomized, Controlled Trial to Compare TOUJEO and TRESIBA in Terms of Glucose Values in Target Range and Variability During Continuous Glucose Monitoring in Patients With Type 1 Diabetes Mellitus $126,429 166 payments
A 12-week Randomized, Controlled Trial to Compare TOUJEO and TRESIBA in Terms of Glucose Values in Target Range and Variability During Continuous Glucose Monitoring in Patients With Type 1 Diabetes Mellitus $39,143 56 payments
A 12-week Randomized, Controlled Trial to Compare TOUJEO and TRESIBA in Terms of Glucose Values in Target Range and Variability During Continuous Glucose Monitoring in Patients With Type 1 Diabetes Me $32,063 52 payments
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis $29,725 9 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function $22,160 8 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi $8,662 1 payment
Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine $5,000 1 payment
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi $4,533 1 payment
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab $3,275 2 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Fu $295 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.